NCT06294574 Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
| NCT ID | NCT06294574 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Breast Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-08-05 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-08-05 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK.
Eligibility Criteria
Inclusion Criteria: * Patients with biopsy clips scheduled for surgery with SCOUT localization Exclusion Criteria: * Patients who didn't have surgery, patients younger than 18 years old * Patients older than 90 years old * Inmates * Non-English speakers
Contact & Investigator
Ceren Yalniz, MD
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT06294574 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 90 Years, studying Breast Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06294574 currently recruiting?
Yes, NCT06294574 is actively recruiting participants. Contact the research team at qmooney@uabmc.edu for enrollment information.
Where is the NCT06294574 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT06294574 clinical trial?
NCT06294574 is sponsored by University of Alabama at Birmingham. The principal investigator is Ceren Yalniz, MD at University of Alabama at Birmingham. The trial plans to enroll 150 participants.